We are an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment.

Innovative medical equipment

We enable healthier lives, everywhere, every day

As the leader in women’s health, we deliver life-changing and life-saving diagnostic, detection, and surgical products that are rooted in science, driven by technology, and inspired by our desire to empower women and help healthcare professionals diagnose and treat their patients with growing certainty, precision, and ever-greater peace of mind.

About Us

Featured Products

picture of 3-Dimensions Mammography System

3Dimensions™ Mammography System
picture of Panther Fusion Assays

Panther Fusion® Assays
picture of Brevera Breast Biopsy System

Brevera® Breast Biopsy System
picture of Aptima Herpes Simplex 1&2 assay

Aptima® Herpes Simplex 1&2 assay

Affirm Prone Breast Biopsy System

Affirm® Prone Breast Biopsy System
picture of Horizon DXA System

Horizon® DXA System
picture of ThinPrep Pap test

ThinPrep® Pap test
picture of Fluoroscan InSight Mini C-arm Extremities Imaging System

Fluoroscan® InSight® Mini C-arm Extremities Imaging System
picture of Hologic SARS-CoV-2 Assays

Hologic SARS-CoV-2 Assays
picture of MyoSure Tissue Removal Suite

MyoSure® Tissue Removal Suite
picture of NovaSure Endometrial Ablation

NovaSure® Endometrial Ablation

Financial Fast Facts

Revenue Highlights 3Q22

Non-GAAP
Revenue ($M) 		3Q22 Reported ∆
Vs 3Q21 		CC ∆ Vs 3Q21
Diagnostics1 $560.1 (15.8%) (13.6%)
Breast Health $282.8 (19.0%) (17.5%)
GYN Surgical $138.1 8.0% 9.7%
Skeletal Health $21.7 (16.1%) (13.6%)
Total Revenue $1,002.7 (14.2%) (12.2%)
Organic Revenue3 $985.8 (14.6%) (12.6%)
Organic ex COVID-194 $773.0 (3.3%) (1.4%)
US Organic $734.6 (2.0%) -
OUS Organic $268.1 (35.9%) (30.5%)

Financial Overview 3Q22

Non-GAAP
In Millions ex. EPS 		3Q22 ∆ vs. 3Q21
Revenue ($M) $1,002.7 (14.2%)
Organic Revenue3 $985.8 (14.6%)
Organic ex COVID-194 $773.0 (3.3%)
Gross Margin 63.3% (280) bps
Operating Expenses $311.2 0.4%
Operating Margin 32.3% (720) bps
Net Margin 24.1% (540) bps
Diluted EPS $0.95 (28.6%)
EBITDA $348.3 (27.9%)

Financial Guidance for Fourth Quarter Fiscal 2022

Non-GAAP 4Q22 Reported vs. 4Q21 CC vs. 4Q21 Organic5 % Increase
Revenue ($M) $840 - $870 (36.2%) to (33.9%) (34.5%) to (32.2%) (34.4%) to (32.1%)
Non-GAAP EPS $0.60 - $0.65 (62.7%) to (59.6%)
GAAP EPS $0.33 - $0.38 (74.2%) to (70.3%)

Financial Guidance for Full Fiscal 2022

Non-GAAP FY22 Reported vs. FY21 CC vs. FY21 Organic5 % Increase
Revenue ($M) $4,750 - $4,780 (15.7%) to (15.1%) (14.4%) to (13.8%) (15.4%) to (14.9%)
Non-GAAP EPS $5.79 - $5.84 (31.2%) to (30.6%)
GAAP EPS $4.98 - $5.03 (30.9%) to (30.2%)

Capital Deployment

Expect strong cash flow in fiscal second quarter and full year 2022

Business development priorities:

  • Tuck-in acquisitions
  • Accretive to revenue, EPS growth rates
  • Attractive ROIC
  • Leverage existing sales channels

Net Debt & Leverage Ratio2

Revenue & CC Growth Rates

2021 Divisional Revenue by Geography

Non-GAAP EPS

% Net Margin

ROIC

  1. Excluding COVID-19 revenues, global diagnostics revenue grew 4.0% on an organic, constant currency basis.
  2. Net debt is total debt minus cash; leverage ratio is principal debt minus cash to TTM adjusted EBITDA.
  3. Organic revenue excludes divestited Blood business as well as acquired Biotheranostics, Diagenode, Mobidiag, and Bolder acquisitions.
  4. Total "organic" revenue excluding COVID-19.
  5. Fiscal 2022 Organic Revenue includes Acessa as part of organic revenue for the full year, whereas Biotheranostics and Diagenode become part of organic revenue in the fiscal third quarter and Mobidiag becomes part of organic revenue in the fiscal fourth quarter.